drugset
drugset / Trial / NCT04321980

A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers

NCT04321980 ↗

Phase 1 Completed 8 enrolled Orpheris, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A clinical study to measure the Safety, Tolerability, and Pharmacokinetics of OP-101 After Subcutaneous Administration in Healthy Volunteers

Timeline

Start
2020-03-19
Primary completion
2020-05-22
Completion
2020-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject ACETYLCYSTEINE ZIDRIMER Small molecule 4 mg/kg Subcutaneous
Subject ACETYLCYSTEINE ZIDRIMER Small molecule 8 mg/kg Subcutaneous

Indications

No indication recorded.